281 related articles for article (PubMed ID: 33184662)
21. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
Cavallari I; Verolino G; Romano S; Patti G
Thromb Haemost; 2020 Feb; 120(2):314-321. PubMed ID: 31785599
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry.
Scognamiglio G; Fusco F; Hankel TC; Bouma BJ; Greutmann M; Khairy P; Ladouceur M; Dimopoulos K; Niwa K; Broberg CS; Miranda B; Budts W; Bouchardy J; Schwerzmann M; Lipczyńska M; Tobler D; Tsai SF; Egbe AC; Aboulhosn J; Fernandes SM; Garr B; Rutz T; Mizuno A; Proietti A; Alonso-Gonzalez R; Mulder BJM; Sarubbi B;
Int J Cardiol; 2021 Jan; 322():129-134. PubMed ID: 32805330
[TBL] [Abstract][Full Text] [Related]
24. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
[TBL] [Abstract][Full Text] [Related]
25. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
26. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study.
Douros A; Renoux C; Coulombe J; Suissa S
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1546-1554. PubMed ID: 28984052
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
[TBL] [Abstract][Full Text] [Related]
28. Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
Yang H; Bouma BJ; Mulder BJM;
Cardiovasc Drugs Ther; 2017 Aug; 31(4):413-417. PubMed ID: 28785894
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
[TBL] [Abstract][Full Text] [Related]
30. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
[TBL] [Abstract][Full Text] [Related]
31. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
32. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
33. Oral anticoagulant therapy in adults with congenital heart disease and atrial arrhythmias: Implementation of guidelines.
Yang H; Heidendael JF; de Groot JR; Konings TC; Veen G; van Dijk APJ; Meijboom FJ; Sieswerda GT; Post MC; Winter MM; Mulder BJM; Bouma BJ
Int J Cardiol; 2018 Apr; 257():67-74. PubMed ID: 29506740
[TBL] [Abstract][Full Text] [Related]
34. Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.
Yang J; Zhang X; Wang XY; Zhang C; Chen SZ; Hu SJ
BMC Cardiovasc Disord; 2019 Nov; 19(1):261. PubMed ID: 31771529
[TBL] [Abstract][Full Text] [Related]
35. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
[TBL] [Abstract][Full Text] [Related]
36. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
37. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.
Raparelli V; Proietti M; Cangemi R; Lip GY; Lane DA; Basili S
Thromb Haemost; 2017 Jan; 117(2):209-218. PubMed ID: 27831592
[TBL] [Abstract][Full Text] [Related]
38. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
39. Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy.
Metzgier-Gumiela A; Skonieczny G; Konieczyńska M; Desteghe L; Heidbuchel H; Undas A
Int J Clin Pract; 2020 Jun; 74(6):e13483. PubMed ID: 32003070
[TBL] [Abstract][Full Text] [Related]
40. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
